An Open-Label, Superiority, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination Versus Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients With Essential Hypertension Uncontrolled by Telmisartan and Amlodipine Combinations
An Open-Label, Superiority, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination Versus Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients With Essential Hypertension Uncontrolled by Telmisartan and Amlodipine Combinations
This study is to compare the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination and Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients with Essential Hypertension Uncontrolled by Telmisartan and Amlodipine Combinations
This is a Phase IV, Randomized, Open-label, Superiority, Comparative study evaluating the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination) versus Telmisartan, Amlodipine, and Hydrochlorothiazide in eledrly patient with essential hypertension uncontrolled by Telmisartan and Amlodipine Combinations.
Inclusion Criteria:
Participants who have been fully informed about the purpose, content, and characteristics of investigational product, and have voluntarily agreed in writing
Aged ≥ 65 with essential hypertension
Patient with uncontrolled essential hypertension at screening
Exclusion Criteria:
Patient who has history of drug allergic reactions
Known hypersensitivity to components of the investigational product
Patient who is unable to stop taking prohibited drugs
Test results showing the following values at screening
Pregnant or lactating women
Patient who is unable to maintain proper night sleep
Malnutrition, starvation, debilitating factors, A person who is being forcibly detained for the treatment of mental or physical
Administration of other investigational products within 3 months prior to screening.
An impossible one who participates in clinical trial by investigator's decision
Seoul, Gyeonggi-do 14647, South Korea